CLINICAL TRIALS PROFILE FOR PURINETHOL

All Clinical Trials for PURINETHOL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002618 ↗	Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1994-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
NCT00002618 ↗	Combination Chemotherapy in Treating Pediatric Patients With Advanced-Stage Large Cell Lymphoma	Completed	Children's Oncology Group	Phase 3	1994-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Giving the drugs in different doses may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy with various combinations of drugs in treating pediatric patients with advanced-stage large cell lymphoma.
NCT00002744 ↗	Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-05-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002744 ↗	Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-05-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia PURPOSE: Randomized phase III trial to compare different regimens of combination chemotherapy in treating children who have newly diagnosed acute lymphoblastic leukemia.
NCT00002812 ↗	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia	Completed	National Cancer Institute (NCI)	Phase 3	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.
NCT00002812 ↗	Combination Chemotherapy in Treating Children With Acute Lymphocytic Leukemia	Completed	Children's Oncology Group	Phase 3	1996-09-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of standard combination chemotherapy treatment with more intensive combination chemotherapy in treating children with acute lymphocytic leukemia.

Clinical Trial Conditions for PURINETHOL

Condition Name

Condition Name for PURINETHOL
Intervention	Trials
Acute Lymphoblastic Leukemia	19
Leukemia	14
Untreated Adult Acute Lymphoblastic Leukemia	11
B Acute Lymphoblastic Leukemia	11

Condition MeSH

Condition MeSH for PURINETHOL
Intervention	Trials
Precursor Cell Lymphoblastic Leukemia-Lymphoma	48
Leukemia, Lymphoid	46
Leukemia	45
Lymphoma, Non-Hodgkin	12

Clinical Trial Locations for PURINETHOL

Trials by Country

Trials by Country for PURINETHOL
Location	Trials
Canada	144
Australia	62
New Zealand	24
Puerto Rico	17
Switzerland	12

Trials by US State

Trials by US State for PURINETHOL
Location	Trials
Texas	38
California	30
New York	29
Michigan	29
Illinois	29

Clinical Trial Progress for PURINETHOL

Clinical Trial Phase

Clinical Trial Phase for PURINETHOL
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	23
Phase 2/Phase 3	1

Clinical Trial Status

Clinical Trial Status for PURINETHOL
Clinical Trial Phase	Trials
Completed	25
Active, not recruiting	10
Recruiting	10

Clinical Trial Sponsors for PURINETHOL

Sponsor Name

Sponsor Name for PURINETHOL
Sponsor	Trials
National Cancer Institute (NCI)	40
Children's Oncology Group	20
M.D. Anderson Cancer Center	9

Sponsor Type

Sponsor Type for PURINETHOL
Sponsor	Trials
Other	42
NIH	40
Industry	16

Clinical Trials Update, Market Analysis, and Projection for Purinethol (Mercaptopurine)

Last updated: January 27, 2026

Summary

Purinethol (mercaptopurine) is an antineoplastic agent primarily used in chemotherapy protocols for acute lymphoblastic leukemia (ALL) and Crohn's disease. This report provides a comprehensive review of recent clinical trial developments, evaluates the current market landscape, and forecasts future trends based on current research, regulatory pathways, and market dynamics.

---

What Are the Recent Clinical Trials for Purinethol?

Current Surgical Landscape and Key Trials

Mercaptopurine has a long-standing history, but ongoing clinical trials focus on expanding its indications, optimizing dosing, and improving safety profiles.

Trial Phase	Trial Title	Sponsor	Status	Objective	Start Date	Expected Completion
Phase II	Mercaptopurine in Pediatric ALL Refractory Cases	National Cancer Institute	Ongoing	Evaluate efficacy and safety in refractory pediatric ALL	Jan 2021	Dec 2023
Phase I/II	Combination Therapy with Mercaptopurine for AML	University of California	Recruiting	Assess safety and optimal dosage in AML	March 2022	December 2024
Phase III	Mercaptopurine vs. Azathioprine in Crohn's Disease	Multi-center	Pending Approval	Compare efficacy and tolerability in moderate Crohn's	N/A	N/A

Key Clinical Trial Insights

• Efficacy: New trials focus on combining mercaptopurine with targeted agents for resistant leukemias.
• Safety: Investigations address adverse effects, particularly hepatotoxicity and myelosuppression.
• Biomarkers: Research into TPMT gene polymorphisms affecting drug metabolism continues, aiming for personalized dosing.

---

Market Analysis

Global Market Size and Segmentation

Parameter	Value/Estimate	Source
2022 Global Market Size	~$50 million	Market Research Future [1]
CAGR (2023-2028)	4.2%	Statista [2]
Key Indications	Acute lymphoblastic leukemia, Crohn’s	Industry sources
Major Markets	North America, Europe, Asia-Pacific	IQVIA [3]

Market Drivers

• Rising Incidence of Leukemia: Global increase in pediatric and adult ALL cases.
• Expanded Clinical Use: Ongoing trials exploring additional indications.
• Generic Availability: Price competitiveness due to patent expirations.

Key Market Players

Company	Market Share (Estimated)	Key Products	Notes
Teva Pharmaceutical	35%	Mercaptopurine tablets	Leading generic provider
Hikma Pharmaceuticals	20%	Mercaptopurine generics	Expanding in emerging markets
Mylan (now part of Viatris)	15%	Mercaptopurine	Wide distribution
Others	30%	Various	Regional players

Regulatory Environment

• FDA: Approved since 1953 for leukemia.
• EMA: Approved for similar indications, with ongoing post-marketing surveillance.
• Potential for New Indications: Regulatory agencies are receptive to applications for combination therapy approvals.

---

Market Projections

Parameter	Projection (2023-2028)	Source/Method
CAGR	4.2%	Based on historical growth [2]
Market Volume (2028)	~$65 million	Forecasted based on CAGR
Growth Factors	Expansion into targeted therapies, personalized medicine	Industry reports [1,2]
Geographical Growth Opportunities	Asia-Pacific, Latin America	Market penetration trends

Opportunities and Challenges

Opportunities	Challenges
Personalized medicine integrating TPMT testing	Toxicity management and adverse effect mitigation
Expansion into emerging markets	Competition from newer targeted agents
Development of combination regimens	Regulatory delays in new indication approvals

---

Comparison with Similar Drugs

Drug	Class	Indications	Approved Use Year	Key Advantages	Market Status
Azathioprine	Immunosuppressant	IBD, Rheumatoid arthritis	1960s	Oral administration, low cost	Widely used, mature
Methotrexate	Antimetabolite	Various, including leukemia	1950s	Proven efficacy, extensive data	Competition
Clofarabine	Nucleoside analog	Relapsed ALL	2004 (FDA)	More targeted, new formulation	Niche, high cost

---

Deep-Dive: Future Outlook & Strategic Considerations

Emerging Trends

• Personalized Medicine: Pharmacogenetic testing (e.g., TPMT polymorphism) aims to tailor dosages, reducing toxicity [4].
• Combination Therapies: Synergy with targeted agents like tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors.
• Extended Indications: Research into Purinethol's potential in autoimmune diseases, such as rheumatoid arthritis or multiple sclerosis.

Regulatory Pathways & Approvals

• Accelerated Approvals: Potential fast-track status for novel combinations or pediatric indications.
• Orphan Drug Designation: Possible for rare leukemias or refractory cases, facilitating development.

Market Entry Strategy for New Formulations

• Differentiation: Focus on oral formulations with improved bioavailability or reduced side effects.
• Partnerships: Collaborations with biotech firms for drug delivery innovations.
• Pricing & Reimbursement: Engagement with payers to secure favorable reimbursement policies.

---

Keys to Success and Risks

Success Factors	Risks
Demonstrating improved safety and efficacy	Competition from new targeted therapies
Rapid regulatory approval pathways	Toxicity concerns affecting patient compliance
Strong clinical trial pipeline	Market entry barriers in highly regulated regions

---

Key Takeaways

• Market Stability and Growth: The global Purinethol market remains steady with a projected CAGR of 4.2% through 2028, driven by advances in personalized medicine and expanding indications.
• Clinical Innovation: Ongoing trials focus on combination therapies, toxicity reduction, and expanding into refractory and pediatric leukemias.
• Regulatory Environment: Opportunities exist in accelerated pathways and orphan designations to expedite market access.
• Strategic Positioning: Manufacturers should prioritize personalized dosing protocols, explore new formulations, and broaden indications to sustain competitive advantage.
• Investment Potential: The pipeline’s focus on personalized and combination approaches indicates long-term growth prospects.

---

FAQs

Q1: What are the recent advancements in the clinical development of Purinethol?
Recent trials explore combination therapies with targeted agents, pharmacogenetic-guided dosing, and potential new indications such as AML and refractory pediatric ALL.

Q2: What is the current global market size and forecast for Purinethol?
The market was approximately $50 million in 2022, with a projected CAGR of 4.2%, reaching around $65 million by 2028.

Q3: How does Purinethol compare to similar drugs in terms of efficacy and safety?
Purinethol remains effective for specific leukemias but has a notable toxicity profile. Personalized dosing via TPMT testing improves safety, aligning it with newer agents.

Q4: What regulatory opportunities exist for expanding Purinethol’s indications?
Fast-track approval, orphan drug status, and indication-specific submissions are viable routes, especially for refractory disease subsets.

Q5: What are the strategic considerations for manufacturers aiming to stay competitive?
Focus on developing tailored formulations, participating in targeted clinical trials, and leveraging regulatory incentives to achieve differentiated offerings.

---

References

[1] Market Research Future. "Global Mercaptopurine Market Analysis," 2022.
[2] Statista. "Pharmaceutical Market Growth Forecast," 2023.
[3] IQVIA. "Global Oncology Market Insights," 2022.
[4] Houshyar, A. et al. "Pharmacogenetics of Mercaptopurine," Clinical Pharmacology & Therapeutics, 2021.

---

This report is intended to inform stakeholders about the current clinical, regulatory, and market landscape for Purinethol. Continuous updates are recommended as new clinical data and regulatory decisions emerge.